Tirzepatide 20mg

Tirzepatide 20mg

Tirzepatide is a peptide that activates GIP and GLP-1 receptors, helping explain its effects on appetite and blood sugar regulation. It helps the body release insulin when needed, slows stomach emptying and reduces food intake. Tirzepatide also has benefits for people suffering with type 2 diabetes or obesity, Tirzepatide is the active ingredient found in name brands like Mounjaro, Zepbound and Wegovy.

Apply for a Trade Account

SEQUORA Tirzepatide 20mg is a research compound that activates GIP and GLP-1 receptors. It is more widely known by its branded name, Mounjaro. Available in vial and prefilled pen formats,we offer a choice of formats to help with appetite regulation, glucose metabolism and related metabolic pathways.

Choose your product format
  • 20mg vial: a 20mg sealed vial of lyophilized powder (freeze dried). This format extends the shelf-life significantly and also allows freezer storage of your Tirzepatide. This vial can then be mixed with Bacteriostatic Water (BAC water) and be used as an injectable Tirzepatide compound.
  • 20mg prefilled pen: A prepared reconstituted Tirzepatide in a 3ml cartridge. This is then inserted into a SEQUORA disposable injector pen for easy use and dosing.

The 20mg figure indicates the total stated tirzepatide content, not the concentration or amount delivered per withdrawal. Please visit the bottom of this page for dosage guidance and advice.

Purity & Verification

All of our products are third party laboratory tested to ensure both purity and verification of the peptide itself.

What is Tirzepatide 20mg used For?

Tirzepatide (namebrand: Mounjaro) is a weight loss medicine, used to treat type 2 diabetes and support weight loss and weight maintenance in adults. It acts on GIP and GLP-1 receptors to help regulate blood sugar, reduce hunger and increase feelings of fullness. For weight management, it is prescribed alongside a reduced-calorie diet and increased physical activity.

What are the benefits of Tirzepatide 20mg?

For people who are overweight or struggle with over-eating, SEQUORA Tirzepatide can reduce hunger and food cravings, making it easier to follow a reduced-calorie diet. Alongside physical activity, it can support weight loss and weight maintenance. It can also improve blood sugar control in people with type 2 diabetes.

Why buy Tirzepatide 20mg from SEQUORA?

SEQUORA Tirzepatide is up to half the price of the namebrand Mounjaro from online and highstreet pharmacy’s. Not only that but it requires no prescription or preapproval process as we sell all of our products as research peptides rather than medication.

Questions & Answers

Is SEQUORA Tirzepatide the same as Mounjaro?

Mounjaro is the namebrand for Eli Lilly’s weight loss medication, however Tirzepatide is the active ingredient in Mounjaro, meaning SEQUORA’s Tirzepatide (20mg/40mg) has the same effects, dosages and protocols as Mounjaro at a massively reduced cost.

None of SEQUORA’s products require a prescription, we can provide this service by selling all of our peptides, blends and compounds as research use only (RUO). This also lets us offer our products with a large discount compared to big name pharma companies.

Do I need to increase my dose every four weeks?

No. After the starting dose is increased to 5mg, further increases are only made if needed and prescribed. You should spend at least four weeks on your current dose before an increase. Do not change dose just because you think you should, rather go what your research and body is telling you, if in doubt always consult a professional.

Common side effects include nausea, diarrhoea, vomiting and constipation, particularly during dose changes. Seek urgent medical help for severe, persistent abdominal pain and always take time off of Tirzepatide if you feel your side effects are unmanageable.

Product Information Guide

Tirzepatide

Product information, handling and safety

Storage

What Temperature should I store my Tirzepatide at?

Safety

What are the best practices for using Tirzepatide safely?

Evidence

The documentation behind Tirzepatide and it's uses

What is Tirzepatide?

Tirzepatide is a peptide that activates GIP and GLP-1 receptors, helping explain its effects on appetite and blood sugar regulation. It helps the body release insulin when needed, slows stomach emptying and reduces food intake. Tirzepatide also has benefits for people suffering with type 2 diabetes or obesity, Tirzepatide is the active ingredient found in name brands like Mounjaro, Zepbound and Wegovy.

Storage & Handling

Storage

Upon delivery store in a refridgerator between 2-8°C.

  • Avoid storing at the very back of the refridgerator.
  • Avoid exposure to heat, direct sunlight and temperature fluctuations.
  • Never freeze your SEQUORA Tirzepatide Pens (Vials are safe to be frozen BEFORE reconstitution only).

Handling

Avoid dropping or heavy-handling of your Tirzepatide.

Please do not freeze your SEQUORA Tirzepatide Pen as this can compromise the Tirzepatide.

Your product has been shipped in secure packaging to prevent any potential issues however if you believe your peptides have been compromised contact us directly.

shelf-life

Your SEQUORA Tirzepatide Pen will last 12 months from the date of manufacture providing you follow the storage instructions provided.

SEQUORA Tirzepatide Vials before reconstitution can last up to 4 years at -5°C

Tirzepatide can be kept at room temperature however it’s shelf life when held at this temperature reduces to 1-2 months.

Safety & Hygiene

pre-use hygiene

Before handling your Tirzepatide, needles or injection material, ensure your research area is clean and clear.

Wash your hands with warm water and soap and allow to dry fully before handling any SEQUORA products to prevent cross contamination or infection risks.

If at any point the cleanliness of your injection or environment is compromised, restart this step.

needle & injection safety

Never re-use or share needles/syringes. Ensure your needle tips or syringe is sealed and new before injection.

Before using your SEQUORA Tirzepatide Pen, using an alcohol swab, wipe the tip of the cartridge after removing the lid to the pen.

If at any point you touch something unhygienic or potentially dirty, re-wash your hands and use new equipment.

post-injection guidance

Ensure that your needle tips, syringes and vials are safely disposed of post-use.

This could mean a sharps bin or safe container. Most needle tips and syringes have removable tops that can be replaced onto the used needle.

Try to keep your injection site clean for atleast 30 minutes post-injection to prevent infection risks.

Potential Tirzepatide Side Effects

Tirzepatide can cause side effects, although not everyone experiences them. This summary does not cover every possible reaction.

Commonly reported side effects

  • Nausea or vomiting
  • Diarrhoea or constipation
  • Stomach pain, bloating or indigestion
  • Tiredness
  • Redness or itching at the injection site

Other important risks

Potential serious effects include inflammation of the pancreas, gallbladder problems and severe allergic reactions. Low blood sugar is more likely when tirzepatide is combined with insulin or certain other diabetes medicines.

When to seek medical help

Stop use and seek urgent medical attention for severe, persistent stomach pain, which may spread to the back, with or without vomiting.

Call 999 immediately for difficulty breathing or sudden swelling of the lips, tongue or throat.

Speak to a healthcare professional if side effects persist, worsen or concern you.

About this information

This summary is based on safety information for licensed tirzepatide medicines. It does not establish the safety, quality or suitability of this product for human use and is not a substitute for medical advice.

Tirzepatide Side Effect Mitigation

Some mild side effects may improve with changes to eating and drinking habits. These measures cannot prevent serious reactions or make an unlicensed product safe.

Nausea and heartburn

  • Eat smaller meals, eat slowly and stop when comfortably satisfied.
  • Try plain foods such as toast, crackers or rice.
  • Avoid fatty, spicy or strong-smelling foods if they worsen symptoms.
  • Avoid lying down soon after eating.

Constipation

  • Drink fluids regularly unless you have been advised to restrict them.
  • Gradually increase fibre from oats, fruit, vegetables and wholegrains.
  • Include gentle movement, such as walking, where possible.
  • Ask a pharmacist for advice if these measures do not help.

Diarrhoea or vomiting

  • Take frequent small sips of fluid.
  • Eat small amounts of food as tolerated.
  • Ask a pharmacist whether an oral rehydration solution is appropriate.

When to get advice

Contact a healthcare professional if symptoms persist or worsen. Seek prompt medical advice if you cannot keep fluids down, pass less urine or feel lightheaded. Discuss troublesome side effects with your prescriber before any planned dose increase.

Symptoms requiring urgent help

Stop use and seek urgent medical attention for severe, persistent stomach pain, particularly if it spreads to the back. Call 999 for difficulty breathing or sudden swelling of the lips, tongue or throat. Do not try to manage these symptoms with dietary changes.

About this information

This advice relates to prescribed tirzepatide treatment. It does not establish the safety, quality or suitability of a SEQUORA product for human use and does not replace individual medical advice.

Dosing Guidance For Tirzepatide 20mg

Tirzepatide is administered once weekly. The schedule below summarises typical dosing information. Individual treatment and dose changes require a medical assessment.

Pen strength: 20 mg in a final volume of 2.4 ml. Calculated dial settings assume delivery of 0.01 ml per dial unit. Check pen strength before every administration.

Dose Frequency 20 mg pen dial setting Stage and duration
2.5 mg Once weekly 30 Starting dose for the first 4 weeks.
5 mg Once weekly 60 Following the starting stage. A recommended maintenance dose.
7.5 mg Once weekly Exceeds single-dial capacity Only after at least 4 weeks on 5 mg.
10 mg Once weekly Exceeds single-dial capacity Only after at least 4 weeks on 7.5 mg. A recommended maintenance dose.
12.5 mg Once weekly Exceeds single-dial capacity Only after at least 4 weeks on 10 mg.
15 mg Once weekly Exceeds single-dial capacity Only after at least 4 weeks on 12.5 mg. Maximum adult weekly dose.

Dose increases are not automatic

Not everyone needs the maximum dose. Further increases depend on response and tolerability. Do not change your dose without doing your own research or seeking advice from a medical professional.

Understanding the figures

Doses are expressed in milligrams per weekly administration. Each numbered dial of the pen delivers 0.01ml of liquid or 1 Unit. The SEQUORA 20mg Tirzepatide Pen contains 2.4ml of reconstituted Tirzepatide meaning every 1 dial = Approximately 0.0833 mg of Tirzepatide.

Device limits and verification

The maximum dial setting is 60. “Exceeds single-dial capacity” means the listed dose cannot be delivered in one dialled administration using that strength. This table does not provide instructions for combining injections, if you feel you need a larger dose you should purchase the 40mg Tirzepatide Pen instead.